StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.39−0.61 (-5.08%)

Close on Nov 19, 2026Market cap $225.83MP/E –Yield –

Keros Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Keros Therapeutics's pe ratio was 4.8× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20264.8×−8.4
2025Dec 31, 202513.2×–

More Keros Therapeutics figures

See a number that looks wrong?